Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?

Author(s): Florentina Kubizek, Britta Eggenreich, Oliver Spadiut*

Journal Name: Protein & Peptide Letters

Volume 24 , Issue 8 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Over the last years, a novel class of anti-cancer drugs named antibody-drug conjugates (ADCs) has been developed. Due to their limited off-target toxicity but highly potent cytotoxicity at tumor sites, ADCs have proven to be a good alternative to ordinary cancer treatment, such as chemotherapy or combination therapy. Numerous enhancements in antibody-drug engineering led to highly potent tumor targeting drugs with a wide therapeutic window. Two ADCs (Brentuximab vedotin and Trastuzumab emtansine) are already on the market and many others are in clinical trials. However, unstable linkers, low drug potency and unwanted bystander-effects are only some of the drawbacks of ADCs. Enzymes used in combination with prodrugs happen to be a promising alternative. The glyco-enzyme horseradish peroxidase (HRP) has proven to activate the hormone indole-3-acetic acid (IAA) to a highly potent cytotoxic drug. This combination of IAA and HRP has been investigated for the use in strategies such as gene-directed enzyme prodrug therapy (GDEPT) and antibody-directed enzyme prodrug therapy (ADEPT). This article reviews the current state of research in ADC engineering and describes the potential major enhancements through use of glycoenzymes in combination with a prodrug.

Keywords: Antibody-drug conjugates, linker, cytotoxic payload, horseradish peroxidase, indole-3-acetic acid, antibodydirected enzyme prodrug therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [686 - 695]
Pages: 10
DOI: 10.2174/0929866524666170724105211
Price: $65

Article Metrics

PDF: 36